Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
RESEARCH TOOLSreports
Holding OLMA?
Track your performance easily
OLMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.51 - $17.79
Previous Close$12.06
Volume660.16K
Average Volume (3M)478.82K
Market Cap
$679.18M
Enterprise Value$442.04M
Total Cash (Recent Filing)$239.10M
Total Debt (Recent Filing)$1.96M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Mar 03, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.06
Shares Outstanding57,266,358
10 Day Avg. Volume352,096
30 Day Avg. Volume478,819
Standard Deviation0.28
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)3.15
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.08
Forecast
1Y Price Target
$28.83Price Target Upside130.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Olema Pharmaceuticals News
PremiumCompany Announcements
Olema Pharmaceuticals Advances Breast Cancer Treatment Trials
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsOlema's KAT6 inhibitor, OP-3136, has shown compelling preclinical combination data with palazestrant.
Market PositionOlema may hold a relatively dominant position in the KAT6 inhibitor space due to their pipeline assets compared to Pfizer and Menarini.
Stock PerformanceShares of OLMA were up again, +22.87% on the heels of Pfizer’s presentation on its KAT6 inhibitor.
Bears Say
Financial PerformanceOLMA reported 2Q24 results with a net loss of ($30.4MM), primarily due to increased spending on clinical development activities.
Investor SentimentThe short interest in Olema's stock is relatively high, at 17.2% of the float.
Safety ConcernsThe most frequent Grade 3 or higher treatment-related adverse event was neutropenia.
---
Ownership Overview
31.28% Insiders
11.01% Mutual Funds
0.23% Other Institutional Investors
46.74% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $8.51 and its highest was $17.79 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Currently, no data Available
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Mar 03, 2025 which is in 113 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 57,266,357 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Among the largest hedge funds holding Olema Pharmaceuticals’s share is Woodline Partners LP. It holds Olema Pharmaceuticals’s shares valued at 9M.
---
Olema Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.83 (130.27% Upside)
$28.83 (130.27% Upside)
Hedge Fund Trend
Increased
By 119.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.30%
12-Months-Change
Fundamentals
Return on Equity
-56.40%
Trailing 12-Months
Asset Growth
43.31%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
---
OLMA Stock 12 Month Forecast
Average Price Target
$28.83
▲(130.27% Upside)
Technical Analysis
Best Analysts Covering OLMA
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+90.73%
reiterated a buy rating 18 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +90.73% per trade.
---